SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Centocor ( CNTO )
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
965 13 0 CNTO
Emcee:  PawPr Type:  Unmoderated
Introduction Market Data Compact
This company is the next Amgen. Its drug to prevent occlusion of coronary arteries after angioplasty is so good the FDA asked them to
STOP their placebo-controlled trials because the benefits of the drug were so obvious. Formal approval of the drug for this indication is
forthcoming, and the worldwide market is HUGE! They also have a drug
for inflammatory bowel disease in the pipeline and I believe the soon to be announced results will be quite impressive.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
965MorphoSys Announces Second Clinical Milestone in Therapeutic Antibody Program 1Germanecki-12/11/2008
964CNTO 888, a human mAb specific for human MCP-1, was obtained by antibody phage dGermanecki-11/26/2008
963Are you sure this is the Morphosys compound? I couldn't find any mention onghmm-11/25/2008
962Centocor has started a P2 with a Morphosys-mAB! The Symbol of Morphosys-ADR is Germanecki-11/25/2008
961 I commented on this news in the "munch" thread: Message 10594147 PeBiomaven-7/21/1999
960 J&J to buy Centocor for $4.9 billion in stock cbs.marketwatch.comsilInv-7/21/1999
959 If CNTO was a good pick at $30, it's a great pick at $41, since JNJ is repoHenry Niman-7/21/1999
958 BB Biotech expanded position in CNTO to core position (7%). See press-release,Jongmans-7/8/1999
957 I am biased, but from what I understand Isis is can't keep up with RimicadeDutch-6/23/1999
956 Thread and Dutch: --Got any opinion on Isis-2302 vs. Remicade. I am just starMike McFarland-6/23/1999
955 Thanks, will check it out. CNTO would have been a pretty good pick at 30 when SG-6/20/1999
954 Noticed you are looking for "the big kill"; you may very well find itDutch-6/20/1999
953 Thanks, am member in good standing there! SGSG-6/14/1999
952 Try the CCFA.org, you might be able to get an unbiased POV. Dutch-6/13/1999
951 Many thanks; actually my teenage son with Crohn's- real bad illness. StocSG-6/13/1999
950 RE: Nucleotide..... At one time he posted frequently. He went into semi-retirtewdwr-6/13/1999
949 Did "nucleotide.." poster on ISIP do more than 2 posts? Am trying toSG-6/12/1999
948 Check out poster ShadowDoctor... messages.yahoo.com Seems to be knowledgable.tewdwr-6/12/1999
947 Anybody awake here? Any Rheumatologist who is able to tell us her/his take on Alfredo Nova-6/12/1999
946 Sort of a clear opinion. Thanks. Peter...... this sounds like something thscaram(o)uche-6/7/1999
945 The GNE/Roche deal is good news for CNTO relating to the Retavase litigation. FBiomaven-6/7/1999
944 CNTO is still in play. Check out Business Week, 5-31-99 issue p.52 - In Businetewdwr-5/23/1999
943 Never thought the JNJ was compatible .... LILY problem....but who knows, right?FNS-5/13/1999
942 I appreciate this response. I agree with what you said: a deal is not a deal Rhino-5/13/1999
941 As per my previous post, good ole CNTO is its worst enemy ---- just can't FNS-5/13/1999
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News